Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Kakolyris S, et al. Among authors: athanasiadis a. Oncology. 2008;74(1-2):31-6. doi: 10.1159/000138977. Epub 2008 Jun 10. Oncology. 2008. PMID: 18544957 Clinical Trial.
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V; Lung Cancer Subgroup, Hellenic Oncology Research Group. Agelaki S, et al. Among authors: athanasiadis a. Oncology. 2004;66(3):192-6. doi: 10.1159/000077994. Oncology. 2004. PMID: 15218309 Clinical Trial.
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: athanasiadis a. Am J Clin Oncol. 2015 Feb;38(1):17-22. doi: 10.1097/COC.0b013e3182893f13. Am J Clin Oncol. 2015. PMID: 23563209
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V. Stathopoulos GP, et al. Among authors: athanasiadis a. Ann Oncol. 2004 Feb;15(2):224-9. doi: 10.1093/annonc/mdh065. Ann Oncol. 2004. PMID: 14760113 Free article. Clinical Trial.
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D. Georgoulias V, et al. Among authors: athanasiadis a. Br J Cancer. 2005 Oct 3;93(7):763-9. doi: 10.1038/sj.bjc.6602748. Br J Cancer. 2005. PMID: 16175189 Free PMC article. Clinical Trial.
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: athanasiadis a. Br J Cancer. 2006 Mar 27;94(6):798-805. doi: 10.1038/sj.bjc.6603011. Br J Cancer. 2006. PMID: 16508637 Free PMC article. Clinical Trial.
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A, Kouroussis Ch, Ziras N, Kalbakis K, Georgoulias V, Souglakos J. Vamvakas L, et al. Among authors: athanasiadis a. Crit Rev Oncol Hematol. 2010 Oct;76(1):61-70. doi: 10.1016/j.critrevonc.2009.08.003. Epub 2009 Sep 3. Crit Rev Oncol Hematol. 2010. PMID: 19729318 Clinical Trial.
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece. Mavroudis D, et al. Among authors: athanasiadis a. Ann Oncol. 2016 Oct;27(10):1873-8. doi: 10.1093/annonc/mdw274. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502729 Free article. Clinical Trial.
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: athanasiadis e, athanasiadis a. Ann Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193. Ann Oncol. 2019. PMID: 31228203 Free article.
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: athanasiadis a. Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28. Breast Cancer Res Treat. 2010. PMID: 19636702 Clinical Trial.
333 results